{"title":"Characteristics of unsuccessful reactive responses to lateral loss of balance in people with stroke.","authors":"Shirley Handelzalts, Nachum Soroker, Itshak Melzer","doi":"10.1080/01616412.2024.2394327","DOIUrl":"10.1080/01616412.2024.2394327","url":null,"abstract":"<p><strong>Purpose: </strong>The effectiveness of reactive responses to a sudden loss of balance is a critical factor that determines whether a fall will occur. We examined the strategies and kinematics associated with successful and unsuccessful balance recovery following lateral loss of balance in people with stroke (PwS).</p><p><strong>Methods: </strong>Eleven PwS were included in the analysis. They were exposed to unannounced right and left horizontal surface translations and demonstrated both successful and unsuccessful balance responses at the same perturbation magnitude. Reactive step strategies and kinematics were investigated comparatively in successful and unsuccessful recovery tests.</p><p><strong>Results: </strong>The crossover strategy was used in most of the unsuccessful tests (7/11) while the unloaded-leg side-step in the successful tests (6/11). There were no significant differences in the reactive step initiation time in unsuccessful vs. successful tests. However, the step execution time, step length and center of mass displacement were significantly higher during the first recovery step in unsuccessful tests.</p><p><strong>Conclusions: </strong>PwS have difficulties in controlling and decelerating the moving center of mass following a lateral loss of balance. The increased step time and step length of the first reactive step in unsuccessful vs. successful tests suggest the crossover step strategy may be ineffective for PwS.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1095-1104"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Relationship between skeletal muscle mass change and swallowing function improvement among stroke patients with dysphagia during rehabilitation.","authors":"Kenta Kudaka, Keisuke Sato, Yuhki Nakayama, Masaki Koike, Takahiro Ogawa","doi":"10.1080/01616412.2024.2423587","DOIUrl":"10.1080/01616412.2024.2423587","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this study was to evaluate the relationship between changes in skeletal muscle mass and improvements in swallowing function in stroke patients with dysphagia during rehabilitation.</p><p><strong>Methods: </strong>The study included 145 patients with a stroke or dysphagia. The two groups were divided into two groups: those with improved skeletal muscle mass index (SMI) at discharge and those without. Clinical data, including SMI, and Mann Assessment of Swallowing Ability (MASA), were collected from the database.</p><p><strong>Results: </strong>The increase in MASA was significantly higher in the group with increased SMI than in the group with no increase in SMI. In the multivariate analysis, the duration of rehabilitation and the group with increased SMI were associated with increased MASA.</p><p><strong>Conclusion: </strong>SMI gain and the duration of rehabilitation per day were associated with improved swallowing function in patients with stroke.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1167-1173"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurological ResearchPub Date : 2024-12-01Epub Date: 2024-08-28DOI: 10.1080/01616412.2024.2395069
Jianglian Zhu, Yundong Zhang
{"title":"Dexmedetomidine inhibits the migration, invasion, and glycolysis of glioblastoma cells by lactylation of c-myc.","authors":"Jianglian Zhu, Yundong Zhang","doi":"10.1080/01616412.2024.2395069","DOIUrl":"10.1080/01616412.2024.2395069","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM) is a brain tumor with poor prognosis. Dexmedetomidine (Dex) regulates the biological behaviors of tumor cells to accelerate or decelerate cancer progression.</p><p><strong>Objective: </strong>We investigated the effects of Dex on the migration, invasion, and glycolysis in GBM.</p><p><strong>Methods: </strong>The concentration of Dex was determined using the cell counting kit-8 assay. The impacts of Dex on biological behaviors of GBM cells were assessed using Transwell assay, XF96 extracellular flux analysis, and western blot. The expression of c-Myc was examined using reverse transcription-quantitative polymerase chain reaction. The lactylation or stability of c-Myc was measured by western blot after immunoprecipitation or cycloheximide treatment.</p><p><strong>Results: </strong>We found that Dex (200 nM) inhibited GBM cell viability, migration, invasion, and glycolysis. C-Myc was highly expressed in GBM cells and was decreased by Dex treatment. Moreover, Dex suppressed lactylated c-Myc levels via suppressing glycolysis, thereby reducing the protein stability of c-Myc. Sodium lactate treatment abrogated the effects of Dex on the biological behaviors of GBM cells.</p><p><strong>Conclusion: </strong>Dex suppressed the migration, invasion, and glycolysis of GBM cells via inhibiting lactylation of c-Myc and suppressing the c-Myc stability, suggesting that Dex may be a novel therapeutic drug for GBM treatment.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1105-1112"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurological ResearchPub Date : 2024-12-01Epub Date: 2024-11-07DOI: 10.1080/01616412.2024.2424574
Filiz Manga Günaydin, Abdulkadir Tunç
{"title":"Prevalence of restless genital syndrome and its impact on quality of life in women with restless legs syndrome.","authors":"Filiz Manga Günaydin, Abdulkadir Tunç","doi":"10.1080/01616412.2024.2424574","DOIUrl":"10.1080/01616412.2024.2424574","url":null,"abstract":"<p><strong>Background: </strong>Restless genital syndrome (RGS), also known as persistent genital arousal disorder, is a distressing condition characterized by unwanted genital arousal in the absence of sexual desire. This study explores the prevalence of RGS in women with restless legs syndrome (RLS), investigates the associated psychological impacts, and assesses the overall effect on quality of life.</p><p><strong>Methods: </strong>This retrospective study included 69 female patients who were diagnosed with RLS at two university medical centers. Data were collected via the RGS diagnostic form, Beck Depression Inventory, Beck Anxiety Inventory, and WHOQOL-BREF quality of life scale. Statistical analyses were used to assess the correlation between RGS and psychological health measures.</p><p><strong>Results: </strong>Approximately 44.9% of the participants with RLS also reported symptoms of RGS. Significant findings included increased nighttime and rest-related exacerbation of RGS symptoms. Compared with those without RGS, participants with RGS presented significantly higher anxiety and depression scores. Moreover, RGS significantly impacted physical health and social relationships, as indicated by lower WHOQOL-BREF scores.</p><p><strong>Conclusion: </strong>This study highlights a significant overlap between RGS and RLS, with substantial impacts on psychological well-being and quality of life. These findings underscore the importance of considering RGS in the clinical management of RLS, suggesting a need for integrated treatment strategies to address both the neurological and the psychological aspects of these conditions.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1174-1180"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurological ResearchPub Date : 2024-12-01Epub Date: 2024-11-03DOI: 10.1080/01616412.2024.2423583
Nooshin Azari, Malahat Rezaee, Dian Dayer, Mohammad Reza Tabandeh
{"title":"Dimethyl itaconate modulates neuroprotective effect on primary rat astrocytes under inflammatory condition by regulating the expression of neurotrophic factors and TrkA/B-P75 receptors.","authors":"Nooshin Azari, Malahat Rezaee, Dian Dayer, Mohammad Reza Tabandeh","doi":"10.1080/01616412.2024.2423583","DOIUrl":"10.1080/01616412.2024.2423583","url":null,"abstract":"<p><strong>Introduction: </strong>Astrocytes, specialized glial cells, are essential for maintaining the central nervous system homeostasis. Inflammatory conditions can disrupt neurotrophic factors and receptor expression in astrocytes, leading to potential central nervous system damage. Itaconate, recently identified for its anti-inflammatory properties, was investigated in this study for its effects on neurotrophic factors in LPS-stimulated primary rat astrocytes.</p><p><strong>Methods: </strong>Primary rat astrocyte cells were isolated from one-day-old Wistar rats and exposed to 1 µg/ml lipopolysaccharide (LPS) for 6 h to stimulate inflammation. The effect of DMI (62.5, 125, and 250 µM for 18 h) on the cell viability of astrocyte cells exposed to LPS was evaluated by the MTT assay. The effects of DMI on the mRNA and protein levels of NGF, BDNF, and GDNF were evaluated using ELISA and qRT-PCR assays. Protein and mRNA levels of neurotrophic factor receptors (TrkA, TrkB, and P75) were evaluated using qRT-PCR and Western blot analyses.</p><p><strong>Results: </strong>The results showed that DMI suppressed astrocytes cell death induced by LPS in a dose-dependent manner. DMI dose-dependently restored the reduced mRNA and protein levels of NGF, BDNF, GDNF, and TrkA and TrkB receptors in LPS-treated astrocytes, but it significantly decreased the p75 expression in the same condition.</p><p><strong>Conclusion: </strong>In conclusion, DMI may be able to support astrocyte survival and functions based on the restoration of neurotrophic factors and their receptors expression in LPS-stimulated astrocyte cells. This suggests that DMI could be a promising therapeutic option for neurodegenerative diseases characterized by inflammation-induced astrocyte dysfunction.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1137-1148"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurological ResearchPub Date : 2024-12-01Epub Date: 2024-11-07DOI: 10.1080/01616412.2024.2403858
Lingyun Huang, Yongjun Chen, Juanchan Sun, Li Xu
{"title":"Exploring the correlation between dietary zinc intake and stroke risk in adults based on NHANES database.","authors":"Lingyun Huang, Yongjun Chen, Juanchan Sun, Li Xu","doi":"10.1080/01616412.2024.2403858","DOIUrl":"10.1080/01616412.2024.2403858","url":null,"abstract":"<p><strong>Objective: </strong>To explore the relationship between dietary zinc intake and stroke.</p><p><strong>Methods: </strong>Subjects from the National Health and Nutrition Examination Survey (NHANES) database (2015 to 2020) were included. Zinc intake was determined using two 24-h dietary recall interviews, and stroke was determined using the Medical Condition Questionnaire (MCQ). Logistic analysis was used to analyze the association between zinc intake and stroke risk. 1:1 nearest neighbor propensity score matching (PSM) was used to reduce selection bias.</p><p><strong>Results: </strong>4705 subjects were included in the study. Multivariate logistic regression analysis before and after matching showed that increased zinc intake was associated with a reduced risk of stroke. And as zinc intake increases, the risk of stroke shows a gradually decreasing trend. Compared with the Q1 group, the risk of stroke in the Q2, Q3, and Q4 groups was reduced by approximately 0.27 times, 0.29 times, and 0.31 times respectively. And there is no interaction between dietary zinc intake and gender in stroke patients.</p><p><strong>Conclusion: </strong>Dietary zinc intake may be a protective factor against stroke, and increasing its intake may prevent or reduce the symptoms of stroke and related diseases.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1113-1121"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"MicroRNA-429 overexpression overcomes imatinib resistance of glioma cells by negatively regulating lysophosphatidic acid receptor 1.","authors":"Jieyao Xia, Zhengyang Peng, Meina Zhang, Qiongqiong Liao, Chubao Liu, Xiong Deng","doi":"10.1080/01616412.2024.2423586","DOIUrl":"10.1080/01616412.2024.2423586","url":null,"abstract":"<p><strong>Background: </strong>Glioma is one of the most aggressive and lethal malignancies in central nervous system. It has been reported that miR-429 is declined in glioma and functions as a tumor suppressor. Nonetheless, the potential role of miR-429 in drug resistance of glioma is still ambiguous.</p><p><strong>Methods: </strong>Stable imatinib-resistant lines U251-AR and T98G-AR were established using glioma cell lines U251 and T98G. Cell apoptosis and cycle were analyzed by flow cytometry, and CCK-8 assay was utilized to measure cell viability. Protein and RNA levels were tested with western blot and RT-qPCR. The predicted binding site was confirmed by dual luciferase reporter assay.</p><p><strong>Results: </strong>Imatinib-resistant U251-AR and T98G-AR cells presented lower level of miR-429 and higher level of LPAR1. MiR-429 overexpression obviously promoted imatinib sensitivity in glioma cells, indicated by the reduced IC50 value, facilitated cell apoptosis and cell cycle arrest at G0/G1 phase, and downregulated multidrug resistance-related proteins. LPAR1 was verified as a direct target of miR-429 and its expression was negatively regulated by miR-429. Additionally, overexpression of LPAR1 restrained the biological function of miR-429 on imatinib chemoresistance.</p><p><strong>Conclusion: </strong>MiR-429 partly sensitized glioma cells to imatinib via downregulation LPAR1, which might provide an approach to overcome imatinib chemoresistance during glioma treatment.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1149-1159"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurological ResearchPub Date : 2024-12-01Epub Date: 2024-10-01DOI: 10.1080/01616412.2024.2407645
Amir Reza Bahadori, Rasa Zafari, Mohammad Amin Fathollahi, Afshan Davari, Mehrdad Sheikhvatan, Sara Ranji, Abbas Tafakhori
{"title":"Effect of deep brain stimulation on sexual dysfunction among patients who had Parkinson's disease: a systematic review and meta-analysis.","authors":"Amir Reza Bahadori, Rasa Zafari, Mohammad Amin Fathollahi, Afshan Davari, Mehrdad Sheikhvatan, Sara Ranji, Abbas Tafakhori","doi":"10.1080/01616412.2024.2407645","DOIUrl":"10.1080/01616412.2024.2407645","url":null,"abstract":"<p><strong>Background: </strong>Patients who have Parkinson's disease (PD) present several non-motor issues, such as sexual dysfunction. Deep brain stimulation (DBS) is a great treatment for PD and could affect both motor and non-motor symptoms of patients.</p><p><strong>Aim: </strong>The main goal of the current study is to evaluate the impact of DBS on the sexual dysfunction among patients with PD.</p><p><strong>Methods: </strong>Five databases (PubMed, Scopus, Embase, Web of Science, and Cochrane Library) were searched for records. Studies that measured the effect of DBS sexual function were included. The risk of bias assessment tool of non-randomized studies of interventions (ROBINS-I) was used to assess the quality of the included studies. The before and after data extraction and statistical analysis were performed using the Comprehensive Meta-analysis software (CMA) version 3.0.</p><p><strong>Result: </strong>Ten studies were included in the systematic review; six of them were eligible to perform a meta-analysis with a total sample size of 532 participants and a mean age of 62.21 ± 1.59 years. All participants performed STN-DBS. The sexual function of participants after STN-DBS implantation significantly increased (SMD = -0.124, 95% CI: -0.209 to -0.038, <i>P</i>-value = 0.005). It also did not have any publication bias. Additionally, their quality of life mounts significantly (SMD = -0.712, 95% CI: -1.002 to -0.422, <i>p</i>-value <0.001).</p><p><strong>Conclusion: </strong>Our systematic review highlights the potential effect of STN-DBS on reducing the sexual dysfunction of patients with PD and boosting their quality of life.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1181-1190"},"PeriodicalIF":1.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neurological ResearchPub Date : 2024-11-01Epub Date: 2024-07-20DOI: 10.1080/01616412.2024.2381381
Hao-Hsiang Hsu, Ai-Hua Lee, Shih-Huang Tai, Liang-Yi Chen, Sheng-Yang Huang, Yi-Yun Chen, Yu-Chang Hung, Tian-Shung Wu, E-Jian Lee
{"title":"Viscolin-mediated antiapoptotic and neuroprotective effects in cortical neurons exposed to oxygen-glucose deprivation and rats subjected to transient focal cerebral ischemia.","authors":"Hao-Hsiang Hsu, Ai-Hua Lee, Shih-Huang Tai, Liang-Yi Chen, Sheng-Yang Huang, Yi-Yun Chen, Yu-Chang Hung, Tian-Shung Wu, E-Jian Lee","doi":"10.1080/01616412.2024.2381381","DOIUrl":"10.1080/01616412.2024.2381381","url":null,"abstract":"<p><strong>Objective: </strong>Previously, we have successfully purified and synthesized viscolin, an agent derived from Viscum coloratum extract, which has shown significant potential in the treatment of stroke. Our study aimed to evaluate the neuroprotective effects of viscolin.</p><p><strong>Methods: </strong>We first assessed the cytotoxicity of viscolin on primary neuronal cultures and determined its antioxidant and radical scavenging properties. Subsequently, we identified the optimal dose-response of viscolin in protecting against glutamate-induced neurotoxicity.</p><p><strong>Results: </strong>Our results demonstrated that viscolin at a concentration of 10 μM effectively reduced neuronal cell death up to 6 hours after glutamate-induced neurotoxicity. Additionally, we investigated the therapeutic window of opportunity and the potential of viscolin in preventing necrotic and apoptotic damage in cultured neurons exposed to oxygen glucose deprivation-induced neurotoxicity. Our findings showed that viscolin treatment significantly reduced DNA breakage, prevented the release of cytochrome c from mitochondria to cytosol, increased the expression of anti-apoptotic protein Bcl-2, decreased the expression of pro-apoptotic protein Bax, and reduced the number of TUNEL-positive cells. Additionally, our in vivo investigation demonstrated a reduction in brain infarction following middle cerebral artery occlusion.</p><p><strong>Conclusion: </strong>Viscolin has potential utility as a therapeutic agent in the treatment of stroke.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"1063-1073"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"High-intensity interval training stimulates remyelination via the Wnt/β-catenin pathway in cuprizone-induced demyelination mouse model.","authors":"Fei Chen, Bing Cheng, Xinqi Xu, Weixing Yan, Qiqi Meng, Jinfeng Liu, Ruiqin Yao, Fuxing Dong, Yaping Liu","doi":"10.1080/01616412.2024.2376310","DOIUrl":"10.1080/01616412.2024.2376310","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to investigate the role of high-intensity interval training (HIIT) in promoting myelin sheath recovery during the remyelination phase in cuprizone (CPZ)-induced demyelination mice and elucidate the mechanisms involving the Wnt/β-catenin pathway.</p><p><strong>Methods: </strong>After 5 weeks of a 0.2% CPZ diet to induce demyelination, a 4-week recovery phase with a normal diet was followed by HIIT intervention. Mice body weight was monitored. Morris water maze (MWM) gauged spatial cognition and memory, while the open field test (OFT) assessed anxiety levels. Luxol fast blue (LFB) staining measured demyelination, and immunofluorescence examined myelin basic protein (MBP) and platelet-derived growth factor receptor-alpha (PDGFR-α). Western blotting analyzed protein expression, including MBP, PDGFR-α, glycogen synthase kinase-3β (GSK3β), β-catenin, and p-β-catenin. Real-time PCR detected mRNA expression levels of CGT and CST.</p><p><strong>Results: </strong>HIIT promoted remyelination in demyelinating mice, enhancing spatial cognition, memory, and reducing anxiety. LFB staining indicated decreased demyelination in HIIT-treated mice. Immunofluorescence demonstrated increased MBP fluorescence intensity and PDGFR-α<sup>+</sup> cell numbers with HIIT. Western blotting revealed HIIT reduced β-catenin levels while increasing p-β-catenin and GSK3β levels. Real-time PCR demonstrated that HIIT promoted the generation of new myelin sheaths. Additionally, the Wnt/β-catenin pathway agonist, SKL2001, decreased MBP expression but increased PDGFR-α expression.</p><p><strong>Discussion: </strong>HIIT promotes remyelination by inhibiting the Wnt/β-catenin pathway and is a promising rehabilitation training for demyelinating diseases. It provides a new theoretical basis for clinical rehabilitation and care programs.</p>","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"996-1007"},"PeriodicalIF":1.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}